| Literature DB >> 23584057 |
Saranya Chandrudu1, Pavla Simerska, Istvan Toth.
Abstract
Since the invention of solid phase synthetic methods by Merrifield in 1963, the number of research groups focusing on peptide synthesis has grown exponentially. However, the original step-by-step synthesis had limitations: the purity of the final product decreased with the number of coupling steps. After the development of Boc and Fmoc protecting groups, novel amino acid protecting groups and new techniques were introduced to provide high quality and quantity peptide products. Fragment condensation was a popular method for peptide production in the 1980s, but unfortunately the rate of racemization and reaction difficulties proved less than ideal. Kent and co-workers revolutionized peptide coupling by introducing the chemoselective reaction of unprotected peptides, called native chemical ligation. Subsequently, research has focused on the development of novel ligating techniques including the famous click reaction, ligation of peptide hydrazides, and the recently reported α-ketoacid-hydroxylamine ligations with 5-oxaproline. Several companies have been formed all over the world to prepare high quality Good Manufacturing Practice peptide products on a multi-kilogram scale. This review describes the advances in peptide chemistry including the variety of synthetic peptide methods currently available and the broad application of peptides in medicinal chemistry.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23584057 PMCID: PMC6270108 DOI: 10.3390/molecules18044373
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Important dates in peptide chemistry.
| 1901 | First published synthesized dipeptide [ |
| 1957 | Boc protecting group [ |
| 1963 | SPPS discovery [ |
| 1967 | HF cleavage [ |
| 1968 | First automated solid phase synthesizer |
| 1970 | BHA resin [ |
| 1973 | Wang resin [ |
| 1976 | Preparative HPLC to purify peptides synthesized by SPPS |
| 1977 | Orthogonal protection [ |
| 1987 | Rink resin [ |
| 1992 | Fast Boc protocol [ |
| 1994 | NCL for protein and peptide synthesis [ |
| 1996 | Pseudoprolines [ |
Scheme 1Schematic representation of peptide production.
Scheme 2SPPS steps with Boc-chemistry.
In situ neutralization (optimized) protocol for microwave-SPPS [31,32].
| Deprotections | Trifluoroacetic acid (Boc chemistry)/20% piperidine in DMF (Fmoc chemistry) | 1–5 min, 0 Watt, rt (Boc chemistry) or 70 °C (Fmoc chemistry) |
| Couplings | Amino acid, HBTU/HATU/HOBt/HOAt/DIC, DIPEA | 5–15 min, 20 Watt,50–70 °C |
Scheme 3Application of NCL for development of a lipoglycopeptide vaccine [43].
Scheme 4Lipoamino acid synthesis (n = a number of carbon atoms in the LAA’s side chain).
Examples of peptide based drugs available on the market.
| Forteo | Osteoporosis | Eli Lilly & Co. | |
| Byetta | Type 2 diabetes | Amylin/Lilly | |
| Fuzeon | HIV | Roche/Trimeris | |
| Firmagon | Prostate cancer | Ferring | |
| Mepact | Bone cancer | Takeda | |
| Natrecor | Heart failure | Johnson & Johnson | |
| Zoladex | Breast and Prostate cancer | AstraZeneca | |
| Copaxone | Multiple sclerosis | Teva Pharmaceuticals | |
| Sandostatin | Neuroendocrine tumors | Novartis Pharmaceuticals | |
| Firazyr | Hereditary angioedema | Jerini | |
| Prialt | Pain | Elan, Azur Pharma | |
| Symlin | Diabetes | Amylin | |
| Nplate | Idiopathic thrombocytopenic purpura | Amgen |